Kooperativer Bibliotheksverbund

In: Journal for ImmunoTherapy of Cancer, BMJ, Vol. 4, No. S1 ( 2016-11)

Type of Medium: Online Resource

ISSN: 2051-1426

URL: Article

DOI: 10.1186/s40425-016-0172-7

Language: English

Publisher: BMJ

Publication Date: 2016

detail.hit.zdb_id: 2719863-7

In: Blood, American Society of Hematology, Vol. 140, No. Supplement 1 ( 2022-11-15), p. 1467-1470

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2022-157691

Language: English

Publisher: American Society of Hematology

Publication Date: 2022

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: The Lancet, Elsevier BV, Vol. 391, No. 10136 ( 2018-06), p. 2236-2271

Type of Medium: Online Resource

ISSN: 0140-6736

URL: Article

DOI: 10.1016/S0140-6736(18)30994-2

Language: English

Publisher: Elsevier BV

Publication Date: 2018

detail.hit.zdb_id: 2067452-1

detail.hit.zdb_id: 3306-6

detail.hit.zdb_id: 1476593-7

SSG: 5,21

In: Supportive Care in Cancer, Springer Science and Business Media LLC, Vol. 20, No. 11 ( 2012-11), p. 2737-2746

Type of Medium: Online Resource

ISSN: 0941-4355 , 1433-7339

URL: Article

DOI: 10.1007/s00520-012-1395-x

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2012

detail.hit.zdb_id: 1463166-0

In: Blood, American Society of Hematology, Vol. 136, No. Supplement 1 ( 2020-11-5), p. 45-46

Abstract: Introduction: More effective, less toxic treatments with convenient administration are needed for patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (B-NHL). Mosunetuzumab (Mosun) is a full-length, fully humanized IgG1 CD20/CD3 bispecific antibody that redirects T cells to engage and eliminate malignant B cells. In an ongoing Phase I/Ib study (GO29781; NCT02500407), Mosun has shown promising efficacy and tolerable safety in pts with R/R B-NHL when administered intravenously (IV) in step-up doses (Bartlett, et al. ASCO 2019, Schuster, et al. ASH 2019). Subcutaneous (SC) administration of Mosun is an alternative approach to minimize the risk of cytokine release syndrome (CRS), a key adverse event (AE) associated with T-cell engaging immunotherapies. Other potential benefits of SC dosing include reduced healthcare resource utilization and increased convenience. This is the first report of clinical data with Mosun SC in pts with R/R B-NHL. Methods: GO29781 is a Phase I/Ib, open-label, multicenter dose-escalation and expansion study of Mosun in R/R B-NHL. Pts included in this report received single-agent Mosun SC on Day 1 of each 21-day Cycle (Q3W), for 8 cycles in pts with complete response (CR) and up to 17 cycles in pts with partial response or stable disease. Dose escalation used a standard 3+3 design; doses from 1.6-20 mg were assessed. Key outcome measures included best objective response (per Cheson 2007 criteria), tolerability and maximum tolerated dose (MTD). Results: As of January 21 2020, 23 pts had received Mosun SC (diffuse large B-cell lymphoma, n=10; follicular lymphoma [FL], n=5; marginal-zone lymphoma [MZL] , n=3; primary mediastinal large B-cell lymphoma, n=2; transformed [tr] FL, n=1; trMZL, n=1; tr nodular lymphocyte-predominant Hodgkin lymphoma, n=1). Median prior systemic therapies was 4 (range: 1-8); five pts (22%) had received prior chimeric antigen receptor T-cell therapy. Thirteen pts (57%) were refractory to last prior therapy and 16 (70%) were refractory to prior anti-CD20 therapy. The MTD was not reached. One dose-limiting toxicity (Grade [Gr] 4 neutropenia; resolved) was observed at dose 1.6mg. Among the 23 safet y-evaluable pts, 22 (96%) experienced ≥1 AE; no AEs led to treatment discontinuation. Common ( & gt;20%) AEs related to Mosun SC were CRS (n=8, 35%), headache (n=5, 22%; all Gr 1) and injection site reaction (n=5, 22%; all Gr 1). All CRS events, graded by Lee criteria (Lee, et al. Blood 2014), occurred during Cycle 1 and were Gr 1 (n=6, 26%) or Gr 2 (n=2, 9%). In contrast to the Q3W fixed-dosing IV cohort, where 15% of pts experienced Gr 2 CRS at doses 0.05-2.8mg, no Gr 2 CRS occurred in the SC cohort at doses & lt;13.5mg. In SC pts, CRS events resolved without tocilizumab treatment, intensive care unit admission or use of vasopressors. One pt required low-flow oxygen. No neurological symptoms (defined as any Preferred Terms in the nervous system disorders and psychiatric disorders system organ class) associated with CRS were reported. Neurological symptoms not associated with CRS occurred in nine pts (39%; all Gr 1) with headache (n=5, 22%) and tinnitus (n=2, 9%) as the most common AEs. Among the 22 efficacy-evaluable pts across all dose levels, overall response rates and CR rates were 86% (6/7) and 29% (2/7) in indolent NHL pts and 60% (9/15) and 20% (3/15) in aggressive NHL pts, respectively. After a median 6.9 months (range: 1.3-22.1) on study for all SC pts, all but one CR pt remained in remission at the cut-off date. The pharmacokinetic (PK) profile of Mosun SC is characterized by a slow absorption rate (observed Tmax at 72 hours post-dose and Cmax reduced by ~70% versus IV) and high bioavailability ( & gt;75%), supporting the use of SC dosing for CRS mitigation. Consistent with reduced CRS, lower peak IL-6 levels were observed with SC dosing, with delayed onset versus Mosun IV. Conclusions: Mosun SC demonstrated a manageable safety profile, encouraging efficacy and a favorable PK profile in heavily pretreated R/R B-NHL pts. CRS events seen in Cycle 1 were mild, transient and required minimal intervention and no Gr ≥3 CRS events were reported. Notably, less frequent Gr 2 CRS events were observed with Mosun SC at 7-fold higher dose levels versus the IV fixed-dosing group. These results support continued dose escalation and optimization of Mosun SC in R/R B-NHL. Updated clinical, PK and biomarker data, including approximately 20 additional pts from an interim expansion cohort, will be presented. Disclosures Matasar: Genentech, Inc.: Consultancy, Honoraria, Research Funding; Daiichi Sankyo: Consultancy; GlaxoSmithKline: Honoraria, Research Funding; IGM Biosciences: Research Funding; Janssen: Honoraria, Research Funding; Pharmacyclics: Honoraria, Research Funding; Immunovaccine Technologies: Honoraria, Research Funding; Merck: Consultancy; Bayer: Consultancy, Honoraria, Research Funding; Juno Therapeutics: Consultancy; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Teva: Consultancy; Rocket Medical: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria. Cheah:Celgene, F. Hoffmann-La Roche, Abbvie, MSD: Research Funding; Celgene, F. Hoffmann-La Roche, MSD, Janssen, Gilead, Ascentage Pharma, Acerta, Loxo Oncology, TG therapeutics: Honoraria. Yoon:Celltrion: Honoraria; Samyang: Research Funding; Amgen, Chongkundang, Celgene, Astrazeneca: Consultancy. Assouline:Takeda: Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria, Research Funding. Bartlett:ADC Therapeutics: Consultancy; Kite, a Gilead Company: Research Funding; Immune Design: Research Funding; Janssen: Research Funding; Forty Seven: Research Funding; BMS/Celgene: Research Funding; Autolus: Research Funding; Merck: Research Funding; Millennium: Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Seattle Genetics: Consultancy, Research Funding; Roche/Genentech: Consultancy, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; BTG: Consultancy; Acerta: Consultancy; Affimed Therapeutics: Research Funding. Ku:F. Hoffmann-La Roche: Honoraria. Giri:Royal Adelaide Hospital: Current Employment. Johnston:MSD: Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche: Membership on an entity's Board of Directors or advisory committees. Flinn:Loxo: Research Funding; Unum Therapeutics: Consultancy, Research Funding; Incyte: Research Funding; BeiGene: Consultancy, Research Funding; Gilead Sciences: Consultancy, Research Funding; MorphoSys: Consultancy, Research Funding; Juno Therapeutics: Consultancy, Research Funding; Nurix Therapeutics: Consultancy; Acerta Pharma: Research Funding; Calithera Biosciences: Research Funding; Celgene: Research Funding; TG Therapeutics: Consultancy, Research Funding; Forma Therapeutics: Research Funding; Novartis: Research Funding; Constellation Pharmaceuticals: Research Funding; Great Point Partners: Consultancy; Genentech, Inc.: Research Funding; IGM Biosciences: Research Funding; Agios: Research Funding; Curio Science: Consultancy; Infinity Pharmaceuticals: Research Funding; Trillium Therapeutics: Research Funding; Pfizer: Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; Teva: Research Funding; Seattle Genetics: Consultancy, Research Funding; Portola Pharmaceuticals: Research Funding; ArQule: Research Funding; Takeda: Consultancy, Research Funding; Merck: Research Funding; Curis: Research Funding; AbbVie: Consultancy, Research Funding; Iksuda Therapeutics: Consultancy; Janssen: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Karyopharm Therapeutics: Research Funding; Kite Pharma: Consultancy, Research Funding; Forty Seven: Research Funding; Triphase Research & Development Corp.: Research Funding; Verastem: Consultancy, Research Funding; Yingli Pharmaceuticals ≠: Consultancy, Research Funding; Rhizen Pharmaceuticals: Research Funding; Johnson & Johnson: Other; Roche: Consultancy, Research Funding; Vincera Pharma: Consultancy; F. Hoffmann-La Roche: Research Funding. Goy:Celgene: Honoraria, Research Funding; Constellation: Research Funding; AbbVie: Research Funding; Hackensack UMC and University of Nebraska: Research Funding; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: leadership role, Research Funding; RCCA/OMI: Current Employment; Janssen: Consultancy, Honoraria, Other: leadership role, Research Funding; Regional Cancer Care Associates/OMI: Current Employment; Infinity Verastem: Research Funding; MD Anderson: Research Funding; Kite, a Gilead Company: Consultancy, Current equity holder in publicly-traded company, Honoraria, Other: leadership role, Research Funding; Bayer: Research Funding; CALBG: Research Funding; PracticeUpdate Oncology: Consultancy; Infinity: Research Funding; Karyopharm: Research Funding; Genentech/Roche: Research Funding; Morphosys: Research Funding; Acerta: Consultancy, Honoraria, Other: leadership role, Research Funding; Xcenda: Consultancy; COTA: Consultancy, Current equity holder in publicly-traded company, Other: leadership role. Tzachanis:Fate: Research Funding; Incyte: Research Funding; Genetech: Research Funding; BMS: Research Funding; Takeda: Consultancy, Speakers Bureau; EUSA Pharma: Consultancy; Jazz: Consultancy; Magenta: Consultancy; Kyowa Kirin: Consultancy; Gilead Sciences: Consultancy, Research Funding, Speakers Bureau. O'Hear:Genentech, Inc.: Current Employment; F. Hoffmann-La Roche: Current equity holder in publicly-traded company. Yin:Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company. To:Genentech, Inc.: Current Employment. Sarouei:Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company. Li:F. Hoffmann-La Roche: Current Employment, Current equity holder in publicly-traded company; Genentech, Inc.: Current Employment. Bender:Genentech, Inc.: Current Employment, Current equity holder in private company. Penuel:F. Hoffmann-La Roche: Current equity holder in publicly-traded company; Genentech, Inc./ F. Hoffmann-La Roche: Current Employment. Huang:F. Hoffmann-La Roche: Current Employment. Budde:AstraZeneca: Speakers Bureau; Merck, Amgen, AstraZeneca, Mustang Therapeutics: Research Funding; F. Hoffmann-La Roche, Kite Pharma: Consultancy. OffLabel Disclosure: Mosunetuzumab (RG7828) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T cells) and CD20 (on the surface of B cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells. Mosunetuzumab is an investigational agent.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2020-135818

Language: English

Publisher: American Society of Hematology

Publication Date: 2020

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: BMJ Open, BMJ, Vol. 6, No. 9 ( 2016-09), p. e010581-

Abstract: We studied the impact of a Housing First (HF) intervention on housing, contact with the justice system, healthcare usage and health outcomes among At Home/Chez Soi randomised trial participants in Toronto, a city with an extensive service network for social and health services for individuals who are experiencing homelessness and mental illness. Methods Participants identified as high needs were randomised to receive either the intervention which provided them with housing and supports by an assertive community treatment team (HF+ACT) or treatment as usual (TAU). Participants (N=197) had in-person interviews every 3 months for 2 years. Results The HF+ACT group spent more time stably housed compared to the TAU group with the mean difference between the groups of 45.8% (95% CI 37.1% to 54.4%, p 〈 0.0001). Accounting for baseline differences, HF+ACT group showed significant improvements over TAU group for community functioning, selected quality-of-life subscales and arrests at some time points during follow-up. No differences between HF+ACT and TAU groups over the follow-up were observed for health service usage, community integration and substance use. Conclusions HF for individuals with high levels of need increased housing stability and selected health and justice outcomes over 2 years in a city with many social and health services. Trial registration number ISRCTN42520374.

Type of Medium: Online Resource

ISSN: 2044-6055 , 2044-6055

URL: Article

DOI: 10.1136/bmjopen-2015-010581

Language: English

Publisher: BMJ

Publication Date: 2016

detail.hit.zdb_id: 2599832-8

In: Critical Care and Resuscitation, Elsevier BV, Vol. 22, No. 2 ( 2020-6-1), p. 133-141

Abstract: BACKGROUND: Contemporary glucose management of intensive care unit (ICU) patients with type 2 diabetes is based on trial data derived predominantly from patients without type 2 diabetes. This is despite the recognition that patients with type 2 diabetes may be relatively more tolerant of hyperglycaemia and more susceptible to hypoglycaemia. It is uncertain whether glucose targets should be more liberal in patients with type 2 diabetes. OBJECTIVE: To detail the protocol, analysis and reporting plans for a randomised clinical trial — the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial — which will evaluate the risks and benefits of targeting a higher blood glucose range in patients with type 2 diabetes. DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: A multicentre, parallel group, open label phase 2B randomised controlled clinical trial of 450 critically ill patients with type 2 diabetes. Patients will be randomised 1:1 to liberal blood glucose (target 10.0–14.0 mmol/L) or usual care (target 6.0–10.0 mmol/L). MAIN OUTCOME MEASURES: The primary endpoint is incident hypoglycaemia ( 〈 4.0 mmol/L) during the study intervention. Secondary endpoints include biochemical and feasibility outcomes. RESULTS AND CONCLUSION: The study protocol and statistical analysis plan described will delineate conduct and analysis of the trial, such that analytical and reporting bias are minimised. TRIAL REGISTRATION: This trial has been registered on the Australian New Zealand Clinical Trials Registry (ACTRN No. 12616001135404) and has been endorsed by the Australian and New Zealand Intensive Care Society Clinical Trials Group.

Type of Medium: Online Resource

ISSN: 2652-9335

Uniform Title: Study protocol and statistical analysis plan for the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial

URL: Issue

URL: Journal

URL: Article

DOI: 10.51893/2020.2

DOI: 10.51893/j

DOI: 10.51893/2020.2.oa3

Language: Unknown

Publisher: Elsevier BV

Publication Date: 2020

In: JAMA, American Medical Association (AMA), Vol. 315, No. 7 ( 2016-02-16), p. 672-

Type of Medium: Online Resource

ISSN: 0098-7484

URL: Article

DOI: 10.1001/jama.2016.0518

Language: English

Publisher: American Medical Association (AMA)

Publication Date: 2016

detail.hit.zdb_id: 2958-0

detail.hit.zdb_id: 2018410-4

SSG: 5,21

In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 3573-3573

Abstract: Background: Cytokine release syndrome (CRS) is a potentially serious complication of T-cell engaging immunotherapy. Effective measures are needed to reduce the rate and severity. In a multicenter Phase I/II study (NCT02500407), the CD20xCD3 bispecific antibody mosunetuzumab (Mosun) showed durable complete responses (CR) and had manageable safety in patients (pts) with late-line R/R B-NHL (Schuster et al. ASH 2019). IV administration with Cycle (C) 1 step-up dosing was an effective strategy for mitigating CRS during C1 (Bartlett et al. ASCO 2019). Fixed-dose SC administration was also a viable strategy for CRS mitigation, owing to the slower rate of Mosun absorption compared with IV (Matasar et al. ASH 2020). A combination of both strategies could further improve the CRS profile. We present safety and efficacy data from the initial cohorts investigating SC Mosun administration with C1 step-up dosing in the Phase I/II study. Methods: All pts had R/R B-NHL with ≥1 prior line of systemic therapy and ECOG PS ≤1. SC Mosun was given in 21-day cycles using two step-up dosing schedules (C1 day [D] 1/C1D8/C1D15 and D1 of subsequent cycles: 5/15/45mg or 5/45/45mg). Mosun was discontinued after C8 in pts who achieved a CR, while pts with a partial response or stable disease continued Mosun for a total of 17 cycles, unless progressive disease or unacceptable toxicity occurred. Primary objectives included evaluation of safety, tolerability, and pharmacokinetics (PK). Responses were evaluated by investigator-assessment of PET/CT scans using Cheson 2007 criteria. CRS is reported using ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019). Results: As of June 21, 2021, 74 pts had been enrolled (5/15/45mg: 38 pts; 5/45/45mg: 36 pts). Median age was 67.0 years (range: 41-88). The most common NHL subtypes were DLBCL (31 pts), FL (21), transformed (tr) FL (10), and MCL (3). 70.0% of pts had Ann Arbor stage III or IV disease. Median number of prior lines of therapy was 3 (range: 1-9). 79.5% of pts were refractory to prior anti-CD20 therapy and 82.4% were refractory to their last prior therapy. Median follow-up for safety was 2.5 months (range: 0.2-7.2). No dose-limiting toxicities were observed during dose-escalation. Common all-Grade (Gr) adverse events (AEs; ≥10% of pts) were injection site reaction (52.7%; Gr 1: 47.3%; Gr 2: 5.4%), CRS (24.3%), fatigue (21.6%), headache (17.6%), rash (13.5%), and pyrexia (10.8%). CRS mostly occurred in C1 and was low Gr in all pts (Gr 1: 17.6%; Gr 2: 6.8%); no Gr ≥3 CRS occurred. Gr 2 CRS occurred with a similar frequency in the 5/15/45mg and 5/45/45mg cohorts (7.9% vs 5.6% of pts, respectively). In the 5/15/45mg cohort, the 3 Gr 2 CRS events occurred after each of the C1 doses, while in the 5/45/45mg cohort, the 2 Gr 2 CRS events occurred after the first 45mg dose. Median duration of CRS was 2 days (range: 1-6) and all events resolved without sequelae. Neutropenia occurred in 12.2% of pts (Gr 2: 2.7%; Gr 3: 6.8%; Gr 4: 2.7%). Febrile neutropenia occurred in only 1 pt (Gr 3). Serious infections occurred in 3 pts (2 pneumonia, both resolved; 1 COVID-19, fatal outcome). No Mosun-related Gr 5 (fatal) AEs or Mosun-related AEs leading to Mosun discontinuation occurred. The PK profile of SC Mosun was consistent with that previously reported, with high bioavailability ( & gt;85%), a slow absorption rate, and a blunted C max. IL-6 and IFN-y kinetics in plasma were similar in both SC cohorts, with modest and delayed increases observed after the initial dose, contrasting with the more marked and rapid increases observed with IV dosing, and consistent with the low frequency and severity of CRS observed. At data cut-off, 38 pts were efficacy evaluable. Responses were observed in 19 pts across all histologies, including 8/10 (80%) pts with R/R FL and 6/17 (35.3%) pts with R/R DLBCL/trFL. Conclusions: SC Mosun administration with C1 step-up dosing has a favorable safety profile in pts with late-line and highly refractory B-NHL, enabling an outpatient treatment schedule without mandatory hospitalizations. Encouragingly, the 5/45/45mg schedule had a low rate of CRS that was similar to the 5/15/45mg schedule, allowing the target dose to be reached earlier. Early response data suggest that the efficacy of Mosun is not compromised by SC dosing. Compared with IV, SC Mosun is likely to improve convenience for pts and efficiency for healthcare providers. Updated efficacy data with longer follow up and depth of response will be presented. Disclosures Bartlett: Affimed: Research Funding; Autolus: Research Funding; Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Forty Seven: Research Funding; Janssen: Research Funding; Kite Pharma: Research Funding; Merck: Research Funding; Millennium: Research Funding; Pharmacyclics: Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Washington University School of Medicine: Current Employment. Giri: Royal Adelaide Hospital: Current Employment. Budde: Genentech, Inc.: Consultancy; Merck, Inc: Research Funding; Amgen: Research Funding; AstraZeneca: Research Funding; Mustang Bio: Research Funding; Novartis: Consultancy; Gilead: Consultancy; Roche: Consultancy; Beigene: Consultancy. Schuster: Celgene: Consultancy, Honoraria, Research Funding; Nordic Nanovector: Consultancy; Novartis: Consultancy, Honoraria, Patents & Royalties, Research Funding; Abbvie: Consultancy, Research Funding; Acerta Pharma/AstraZeneca: Consultancy; Alimera Sciences: Consultancy; BeiGene: Consultancy; Juno Theraputics: Consultancy, Research Funding; Loxo Oncology: Consultancy; Tessa Theraputics: Consultancy; Genentech/Roche: Consultancy, Research Funding; Pharmaclyclics: Research Funding; Adaptive Biotechnologies: Research Funding; Merck: Research Funding; Incyte: Research Funding; TG Theraputics: Research Funding; DTRM: Research Funding. Assouline: Johnson & Johnson: Current equity holder in publicly-traded company; Gilead: Speakers Bureau; Amgen: Current equity holder in publicly-traded company, Research Funding; Novartis: Honoraria, Research Funding; Eli Lilly: Research Funding; Roche/Genentech: Research Funding; Jewish General Hospital, Montreal, Quebec: Current Employment; Takeda: Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria. Matasar: Merck Sharp & Dohme: Current holder of individual stocks in a privately-held company; Juno Therapeutics: Consultancy; Janssen: Honoraria, Research Funding; Daiichi Sankyo: Consultancy; Genentech, Inc.: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; Merck: Consultancy; Teva: Consultancy; TG Therapeutics: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; GlaxoSmithKline: Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Memorial Sloan Kettering Cancer Center: Current Employment; IGM Biosciences: Research Funding; Pharmacyclics: Honoraria, Research Funding; Rocket Medical: Consultancy, Research Funding; ImmunoVaccine Technologies: Consultancy, Honoraria, Research Funding. Canales: Takeda: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy; Sandoz: Honoraria, Speakers Bureau; iQone: Honoraria; Sanofi: Consultancy; Novartis: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Eusa Pharma: Consultancy, Honoraria; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria; Gilead/Kite: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau. Fay: St Vincent's Hosptial, Sydney, Australia: Current Employment. Cheah: BMS: Consultancy, Research Funding; Abbvie: Research Funding; Janssen: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Ascentage Pharma: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; TG therapeutics: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Other: travel, Research Funding. Marlton: BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Queensland Health: Current Employment; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees. Wiebking: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company; F. Hoffmann-La Roche Ltd: Current equity holder in publicly-traded company. Yin: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. To: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company. Li: Genentech, Inc.: Current Employment, Current holder of individual stocks in a privately-held company. Huang: F. Hoffmann-La Roche Ltd: Current Employment. Zhou: Fibrogen China: Ended employment in the past 24 months; Roche Pharma Product Development: Current Employment. Penuel: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company. O'Hear: Genentech, Inc.: Current Employment; F. Hoffmann-La Roche Ltd: Current holder of individual stocks in a privately-held company. Sehn: Novartis: Consultancy; Debiopharm: Consultancy; Genmab: Consultancy. OffLabel Disclosure: Mosunetuzumab is a CD20xCD3 bispecific antibody that redirects T cells to engage and eliminate malignant B cells. Mosunetuzumab is an investigational agent.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2021-147937

Language: English

Publisher: American Society of Hematology

Publication Date: 2021

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Scandinavian Journal of Gastroenterology, Informa UK Limited, Vol. 51, No. 10 ( 2016-10-02), p. 1206-1212

Type of Medium: Online Resource

ISSN: 0036-5521 , 1502-7708

URL: Article

DOI: 10.1080/00365521.2016.1186221

Language: English

Publisher: Informa UK Limited

Publication Date: 2016

detail.hit.zdb_id: 1492631-3